Immune mediated colitis: a surgical perspective
Open Access
- 23 April 2023
- journal article
- review article
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (6) , 1495-1502
Abstract
Background: This study aims to review and summarize the current up to date literature that explore the current treatment approaches to immune mediated colitis and the role of surgical specialties in the landscape of management.Methods: A narrative review of papers was performed following a literature search through Medline, EMBASE and Cochrane Central databases pertaining to immune mediated colitis as an adverse event of cancer immunotherapy.Results: Current guidelines for the diagnosis and treatment of immune mediated colitis mirror the approach to the workup of inflammatory bowel disease and guided by treating oncology and gastroenterology specialties. Immune mediated colitis however relies on surgical specific skills as a consequence of obtaining a diagnosis as well as in the management of complications that may arise.Conclusion: Immune mediate colitis management has largely been under the purview of medical specialties. This review explores the current landscape of managing immune mediated colitis from a surgical perspective and highlights key areas in which surgeons can engage in the multidisciplinary care of this condition. To facilitate prompt diagnosis and management of immune‐mediated colitis, there is an increasing necessity for surgeons to become familiar with the latest multidisciplinary approaches and recommendations.Keywords
This publication has 53 references indexed in Scilit:
- Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitisWorld Journal of Gastroenterology, 2017
- PD‐1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’Histopathology, 2016
- Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitisAlimentary Pharmacology & Therapeutics, 2016
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2016
- Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitisAbdominal Radiology, 2015
- Ipilimumab-induced colitis in patients with metastatic melanomaMelanoma Research, 2015
- Ipilimumab-Associated Colitis: CT FindingsAmerican Journal of Roentgenology, 2013
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV MelanomaClinical Cancer Research, 2009
- Risk of Bowel Perforation in Patients Receiving Interleukin-2 After Therapy With Anti-CTLA 4 Monoclonal AntibodyJournal of Immunotherapy, 2007
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006